- Home
- TPIC vs IMMX Comparison
TPIC vs IMMX Comparison
Compare TPIC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- IMMX
- Stock Information
- Founded
- TPIC 1968
- IMMX 2014
- Country
- TPIC United States
- IMMX United States
- Employees
- TPIC N/A
- IMMX N/A
- Industry
- TPIC Industrial Machinery/Components
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- TPIC Industrials
- IMMX Health Care
- Exchange
- TPIC Nasdaq
- IMMX Nasdaq
- Market Cap
- TPIC 58.4M
- IMMX 61.1M
- IPO Year
- TPIC 2016
- IMMX 2021
- Fundamental
- Price
- TPIC $0.79
- IMMX $2.78
- Analyst Decision
- TPIC Hold
- IMMX Strong Buy
- Analyst Count
- TPIC 7
- IMMX 1
- Target Price
- TPIC $1.68
- IMMX $7.00
- AVG Volume (30 Days)
- TPIC 475.4K
- IMMX 208.2K
- Earning Date
- TPIC 08-11-2025
- IMMX 08-11-2025
- Dividend Yield
- TPIC N/A
- IMMX N/A
- EPS Growth
- TPIC N/A
- IMMX N/A
- EPS
- TPIC N/A
- IMMX N/A
- Revenue
- TPIC $1,373,242,000.00
- IMMX N/A
- Revenue This Year
- TPIC $10.73
- IMMX N/A
- Revenue Next Year
- TPIC $5.56
- IMMX N/A
- P/E Ratio
- TPIC N/A
- IMMX N/A
- Revenue Growth
- TPIC 3.05
- IMMX N/A
- 52 Week Low
- TPIC $0.64
- IMMX $1.26
- 52 Week High
- TPIC $5.15
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- TPIC 39.96
- IMMX 52.62
- Support Level
- TPIC $0.78
- IMMX $2.63
- Resistance Level
- TPIC $0.91
- IMMX $3.20
- Average True Range (ATR)
- TPIC 0.07
- IMMX 0.22
- MACD
- TPIC 0.00
- IMMX -0.04
- Stochastic Oscillator
- TPIC 27.67
- IMMX 13.88
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.